Viloxazine Hydrochloride Patent Expiration
Viloxazine Hydrochloride is Used for managing symptoms of ADHD. It was first introduced by Supernus Pharmaceuticals Inc
Viloxazine Hydrochloride Patents
Given below is the list of patents protecting Viloxazine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Qelbree | US9662338 | Formulations of viloxazine | Apr 02, 2035 | Supernus Pharms |
| Qelbree | US9358204 | Formulations of viloxazine | Feb 07, 2033 | Supernus Pharms |
| Qelbree | US9603853 | Formulations of viloxazine | Feb 07, 2033 | Supernus Pharms |
| Qelbree | US11324753 | Method of treatment of attention deficit/hyperactivity disorder (ADHD) | Sep 04, 2029 | Supernus Pharms |
| Qelbree | US11458143 | Method of treatment of attention deficit/hyperactivity disorder (ADHD) | Sep 04, 2029 | Supernus Pharms |
| Qelbree | US12121523 | Method of treatment of attention deficit/hyperactivity disorder (ADHD) | Sep 04, 2029 | Supernus Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Viloxazine Hydrochloride's patents.
Latest Legal Activities on Viloxazine Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Viloxazine Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Dec, 2023 | US9358204 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US9358204 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US9603853 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US9662338 |
| transaction for FDA Determination of Regulatory Review Period | 29 Nov, 2023 | US9603853 |
| Second letter to regulating agency to determine regulatory review period | 21 Oct, 2022 | US9358204 |
| Second letter to regulating agency to determine regulatory review period | 21 Oct, 2022 | US9603853 |
| Second letter to regulating agency to determine regulatory review period | 21 Oct, 2022 | US9662338 |
| Recordation of Patent Grant Mailed Critical | 04 Oct, 2022 | US11458143 |
| Patent Issue Date Used in PTA Calculation Critical | 04 Oct, 2022 | US11458143 |
Viloxazine Hydrochloride's Family Patents
